Loading...
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.
Blackhall, Fiona H Ross Camidge, D Shaw, A Soria, J Solomon, B Mok, T Hirsh, V Jänne, P Shi, Y Yang, P
Blackhall, Fiona H
Ross Camidge, D
Shaw, A
Soria, J
Solomon, B
Mok, T
Hirsh, V
Jänne, P
Shi, Y
Yang, P
Citations
Altmetric:
Abstract
Crizotinib is a potent, orally administered tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC). We report final results from PROFILE 1005, the largest clinical trial to date for an ALK inhibitor in ALK-positive NSCLC.
Description
Date
2017
Publisher
Collections
Files
Keywords
Type
Article
Citation
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. 2017, 2 (3):e000219 ESMO Open